Overview

Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Objective: To evaluate the safety and efficacy of topical cyclosporine eye drops (Restasis®) for the treatment of epiphora caused by canalicular stenosis secondary to Docetaxel (Taxotere®) treatment for various cancers.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Allergan
Treatments:
Cyclosporine
Cyclosporins
Docetaxel
Fluorometholone
Lubricant Eye Drops
Ophthalmic Solutions
Tetrahydrozoline